Skip to content
Screener

Shares (Diluted) at other companies

CareDx logo
CareDxCDNA
53.1M-3.9%
LivaNova logo
LivaNovaLIVN
56.3M+2.9%
SRT
Strata Critical MedicalSRTA
90.2M+12.9%
Insight Molecular Diagnostics Inc. logo
Insight Molecular Diagnostics Inc.IMDX
34.5M+34.3%
ICU Medical logo
ICU MedicalICUI
25M+1.4%
Stereotaxis logo
StereotaxisSTXS
98.9M+12.7%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.78B-31.3%
Enterprise value$2.73B-26.6%
P/E16.2×-40.3×
P/S4.4×-3.2×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206453
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Provision for income taxes(1,170)(994)
Net income$7,315$25,682
Net income per share:
Basic$0.21$0.76
Diluted$0.20$0.70
Weighted average common shares outstanding:
Basic34,384,20733,721,603
Diluted36,194,02339,914,487

Item 1. Financial Statements (Unaudited)

FAQ

What is TransMedics Group, Inc.'s shares (diluted)?
TransMedics Group, Inc. (TMDX) reported shares (diluted) of 36.2M in Q1 2026.
How has TransMedics Group, Inc.'s shares (diluted) changed year-over-year?
TransMedics Group, Inc.'s shares (diluted) decreased by 9.3% year-over-year, from 39.9M to 36.2M.
What is the long-term trend for TransMedics Group, Inc.'s shares (diluted)?
Over 4 years (2021 to 2025), TransMedics Group, Inc.'s shares (diluted) has grown at a 10.0% compound annual growth rate (CAGR), from 110.3M to 161.8M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about TransMedics Group, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude